| Report | Options implied | Actual move | Market was |
|---|---|---|---|
| 04/30/2026 | ±2.6% | +2.8% | under-priced |
| 02/13/2026 | ±4.0% | -0.4% | over-priced |
| 10/28/2025 | ±2.1% | -0.6% | over-priced |
| 07/29/2025 | ±1.9% | +0.7% | over-priced |
| 04/29/2025 | ±3.0% | +0.4% | over-priced |
| 02/14/2025 | ±2.0% | +0.7% | over-priced |
| 10/29/2024 | ±2.0% | -0.9% | over-priced |
| 07/30/2024 | ±1.8% | +0.9% | over-priced |
| Quarter | EPS (dil.) | Revenue | Net income |
|---|---|---|---|
| Q1 FY2026 | $0.25 | $472M | $523M |
| Q4 FY2025 | — | $410M | $519M |
| Q3 FY2025 | $0.41 | $424M | $629M |
| Q2 FY2025 | $0.34 | $377M | $536M |
HBAN (HBAN) reports imminently, with the next report estimated for 10/27/2026. Across the last 8 reports, options priced an average ±2.4% earnings move while the stock actually moved 0.9% on average — the market has systematically over-priced HBAN's earnings risk. Fundamentals into the print: EPS down 26.5% year-over-year, revenue up 34.5%. QuantLogix's live 5-factor engine currently reads HBAN as a underweight at 45/100.
Implied move is derived from at-the-money option pricing; actual moves are close-to-close on report days. Next-report dates are estimates until confirmed by the company. Educational market analysis, not investment advice. Browse all signal scorecards →